Other News To Note

Cempra Pharmaceuticals Inc., of Chapel Hill, N.C., presented abstracts showing that its antibiotic candidate CEM-101 can be given intravenously without pain in a rabbit ear vein model and provide evidence that inhibition of nicotinic acetylcholine receptors may account for some adverse events associated with telithromycin.